The ibogaine ketamine-abstinence case report generates ≥1 new IND inquiry but no FDA-cleared trial start within 12 weeks, blocked by cardiac (QT) toxicology requirements.

Predicted 2026-08-04 · Resolves 2026-10-27 · clinical · USA

72%

ORACLE CONFIDENCE

⏳ Pending

Every outcome is scored publicly in the ledger.

A single patient story about ibogaine helping someone quit ketamine caught attention, but turning one case into an official clinical trial takes years of safety groundwork — especially because ibogaine can cause dangerous heart rhythms. The FDA (the US drug regulator) requires companies to prove a drug won't kill people before testing it on more patients. No new ibogaine trial targeting ketamine addiction will move from idea to actively recruiting patients by late October 2026.

Resolution rule: YES if, by 2026-10-27, no new ibogaine clinical trial specifically targeting ketamine-abstinence/dependence appears with status 'Recruiting' or 'Active' on clinicaltrials.gov filed after 2026-08-04. Check clinicaltrials.gov (search: ibogaine + ketamine/substance abstinence). Resolves NO if such a trial is registered and active by the check date.

Anecdotes don't clear safety review. Ibogaine's cardiotoxicity mandates preclinical packages regulators won't waive for a single case.

5 new falsifiable predictions, every day at 12:05 PM ET.

Get tomorrow's Oracle →